Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Octreotide Acetate

FDA-approved product (injectable, injection), marketed as Bynfezia Pen, Mycapssa, Octreotide Acetate and 4 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Octreotide Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acromegaly
  • Carcinoid tumor
  • Metastasis
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Somatostatin and analogues
FDA pharmacologic class
Somatostatin Analog FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA61.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli47.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Octreotide Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Octreotide Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokinetics Of Octreotide Acetate Tablets(T25)

    NCT07663318 · start 2026-06-25

    Registered record
    Registry ID
    NCT07663318
    Conditions
    Acromegaly
    Interventions
    T25-Fast; Mycapssa; T25-Fed
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2026-06-25
    Completion
    2026-07-24
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly
    InterventionT25-Fast; Mycapssa; T25-Fed
    PhasePhase 1
    Registry statusCompleted

  • Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

    NCT07087054 · start 2025-11-19

    Registered record
    Registry ID
    NCT07087054
    Conditions
    Carcinoid Syndrome; Carcinoid; Carcinoid Tumor; Carcinoid Tumor of Ileum; Carcinoid Tumor of Cecum; Carcinoid Tumor of Liver; Carcinoid Tumor of Pancreas; Carcinoid Syndrome Diarrhea; Carcinoid Intestine Tumor
    Interventions
    Paltusotine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-11-19
    Completion
    2030-01
    Enrolment
    141

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoid Syndrome; Carcinoid; Carcinoid Tumor; Carcinoid Tumor of Ileum +5 more
    InterventionPaltusotine; Placebo
    PhasePhase 3
    Registry statusRecruiting

  • Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

    NCT06865677 · start 2025-06-09

    Registered record
    Registry ID
    NCT06865677
    Conditions
    Recurrent Platinum Resistant Epithelial Ovarian Carcinoma; Recurrent Epithelial Endometrial Carcinoma; Recurrent Epithelial Cervical Carcinoma
    Interventions
    Sacituzumab Govitecan; EKG; Brain MRI; CT scans; Tumor biopsy; Loperamide; Octreotide; Diphenoxylate/Atropine; Antiemetics
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2025-06-09
    Completion
    2025-07-01
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Platinum Resistant Epithelial Ovarian Carcinoma; Recurrent Epithelial Endometrial Carcinoma; Recurrent Epithelial Cervical Carcinoma
    InterventionSacituzumab Govitecan; EKG; Brain MRI; CT scans +5 more
    PhasePhase 2
    Registry statusTerminated

  • Octreotide vs. Splenic Artery Ligation for Portal Flow Modulation in Living Donor Liver Transplants (SCALOP Trial)

    NCT06974344 · start 2025-06-01

    Registered record
    Registry ID
    NCT06974344
    Conditions
    Small-for-Size Syndrome
    Interventions
    Octreotide (drug); Splenic Artery Ligation (SAL)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2025-06-01
    Completion
    2030-09-01
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmall-for-Size Syndrome
    InterventionOctreotide (drug); Splenic Artery Ligation (SAL)
    PhasePhase 4
    Registry statusNot yet recruiting

  • Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

    NCT06784752 · start 2025-05-30

    Registered record
    Registry ID
    NCT06784752
    Conditions
    Somatostatin Receptor Positive (SSTR+); Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
    Interventions
    [177Lu]Lu-DOTA-TATE; Octreotide LAR
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-05-30
    Completion
    2034-01-23
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSomatostatin Receptor Positive (SSTR+); Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
    Intervention[177Lu]Lu-DOTA-TATE; Octreotide LAR
    PhasePhase 3
    Registry statusRecruiting

  • 177Lu-DOTATATE for Recurrent Meningioma

    NCT06326190 · start 2025-03-10

    Registered record
    Registry ID
    NCT06326190
    Conditions
    Recurrent Meningioma
    Interventions
    Local standard of Care; 177Lu-DOTATATE
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-03-10
    Completion
    2028-12-22
    Enrolment
    136

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Meningioma
    InterventionLocal standard of Care; 177Lu-DOTATATE
    PhasePhase 2
    Registry statusRecruiting

  • Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours

    NCT06345079 · start 2024-10-14

    Registered record
    Registry ID
    NCT06345079
    Conditions
    Neuroendocrine Tumors
    Interventions
    Cessation of somatostatin analogues; Continuation of somatostatin analogues
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-10-14
    Completion
    2028-06
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroendocrine Tumors
    InterventionCessation of somatostatin analogues; Continuation of somatostatin analogues
    PhasePhase 2
    Registry statusRecruiting

  • A Clinical Trial to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Octreotide Long-acting Injection in Patients With Acromegaly

    NCT07814651 · start 2024-04-16

    Registered record
    Registry ID
    NCT07814651
    Conditions
    Acromegaly
    Interventions
    SYHX2008; Sandostatin LAR
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2024-04-16
    Completion
    2026-04-23
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly
    InterventionSYHX2008; Sandostatin LAR
    PhasePhase 2
    Registry statusCompleted

  • A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors

    NCT06300216 · start 2024-03-26

    Registered record
    Registry ID
    NCT06300216
    Conditions
    Neuroendocrine Tumors
    Interventions
    Octreotide microspheres
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2024-03-26
    Completion
    2028-05-26
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroendocrine Tumors
    InterventionOctreotide microspheres
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

    NCT05918302 · start 2023-10-27

    Registered record
    Registry ID
    NCT05918302
    Conditions
    Neuroendocrine Tumors; Lung Neuroendocrine Neoplasm; Thymus Neoplasms
    Interventions
    177Lu-edotreotide; Everolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-10-27
    Completion
    2029-10
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroendocrine Tumors; Lung Neuroendocrine Neoplasm; Thymus Neoplasms
    Intervention177Lu-edotreotide; Everolimus
    PhasePhase 3
    Registry statusRecruiting

  • "Receptor Radionuclide Therapy With 177Lu-DOTATOC

    NCT06045260 · start 2023-09-13

    Registered record
    Registry ID
    NCT06045260
    Conditions
    Neuroendocrine Tumors; Paraganglioma; Pheochromocytoma
    Interventions
    177Lu-DOTATOC
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-09-13
    Completion
    2027-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroendocrine Tumors; Paraganglioma; Pheochromocytoma
    Intervention177Lu-DOTATOC
    PhasePhase 2
    Registry statusRecruiting

  • Pancreatic Clamp in NAFLD

    NCT05724134 · start 2023-08-29

    Registered record
    Registry ID
    NCT05724134
    Conditions
    Insulin Resistance; Prediabetic State; Hyperinsulinemia; Non-Alcoholic Fatty Liver Disease; Obesity
    Interventions
    Insulin human; Octreotide Acetate; Glucagon; Growth Hormone, Human; [6,6-2H2] D-glucose; 20% D-glucose (aq); BOOST Plus; CORE Bar; Harvard Apparatus PHD ULTRA CP syringe pump; Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-08-29
    Completion
    2025-09-24
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsulin Resistance; Prediabetic State; Hyperinsulinemia; Non-Alcoholic Fatty Liver Disease +1 more
    InterventionInsulin human; Octreotide Acetate; Glucagon; Growth Hormone, Human +6 more
    PhasePhase 1
    Registry statusCompleted

  • Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.

    NCT06085976 · start 2023-08-14

    Registered record
    Registry ID
    NCT06085976
    Conditions
    Hepatic Carcinoma; Hepatic Metastasis
    Interventions
    Octreotide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2023-08-14
    Completion
    2025-11-30
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Carcinoma; Hepatic Metastasis
    InterventionOctreotide; Placebo
    PhasePhase 2
    Registry statusUnknown

  • Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.

    NCT05387603 · start 2022-11-01

    Registered record
    Registry ID
    NCT05387603
    Conditions
    Neuroendocrine Tumors
    Interventions
    177Lu-DOTATOC; Capecitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2022-11-01
    Completion
    2026-10-01
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroendocrine Tumors
    Intervention177Lu-DOTATOC; Capecitabine
    PhasePhase 3
    Registry statusRecruiting

  • Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

    NCT05477576 · start 2022-03-24

    Registered record
    Registry ID
    NCT05477576
    Conditions
    GEP-NET; Gastroenteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumor Disease; Neuroendocrine Tumors; Carcinoid; Carcinoid Tumor; Pancreatic NET
    Interventions
    RYZ101; Everolimus; Sunitinib; Octreotide; Lanreotide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2022-03-24
    Completion
    2030-12
    Enrolment
    338

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGEP-NET; Gastroenteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumor Disease; Neuroendocrine Tumors +3 more
    InterventionRYZ101; Everolimus; Sunitinib; Octreotide +1 more
    PhasePhase 3
    Registry statusRecruiting